Prostate Cancer NEWS You Can Use  
 
Us TOO news e-messages
 Us TOO Prostate Cancer NEWS You Can Use

Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
By a News Reporter-Staff News Editor at Clinical Trials Week -- Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who ...

New non-invasive technique could revolutionize the imaging of metastatic cancer
By a News Reporter-Staff News Editor at Clinical Trials Week -- Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. In preclinical animal models of metastatic prostate cancer, scientists at Virginia Commonwealth University Massey Cancer ...

Blood test could identify when cancer treatment has become detrimental
By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Some treatments for prostate cancer, while initially effective at controlling the disease, not only stop working over time but actually start driving tumour growth, a major new study shows (see also Prostate Cancer). Researchers identified the emergence of drug-resistant cancer cells by testing repeated blood samples from ...

Pitt study uncovers prostate cancer mystery
Sept. 16--No method currently exists to gauge the aggressiveness of prostate cancer, putting the patient and his doctors into a quandary about the proper treatment strategy. Should they be aggressive or just watchfully wait? Now a study from the University of Pittsburgh School of Medicine has identified eight gene mutations known as gene fusions that signal aggressive forms of prostate cancer, ...

Findings from University of Michigan Provides New Data on Prostate Cancer (Risk of Second Primary Tumors in Men Diagnosed With Prostate Cancer) (Risk...
Findings from University of Michigan Provides New Data on Prostate Cancer (Risk of Second Primary Tumors in Men Diagnosed With Prostate Cancer) (Risk of Second Primary Tumors in Men Diagnosed With Prostate Cancer) By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Oncology. According to news reporting originating from Ann Arbor, Michigan, by NewsRx ...

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as...
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer By a News Reporter-Staff News Editor at Biotech Week -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that patient enrollment has been completed in the Phase 3 ...

Genetic testing can identify men at 6-fold increased risk of prostate cancer
By a News Reporter-Staff News Editor at Cancer Weekly -- Scientists can now explain a third of the inherited risk of prostate cancer, after a major international study identified 23 new genetic variants associated with increased risk of the disease (see also Clinical Trials and Studies). The study brings the total number of common genetic variants linked to prostate cancer to 100, and testing ...

Prostate Cancer Awareness Month - Stop Random Biopsies
By a News Reporter-Staff News Editor at Cancer Weekly -- Prostate Oncology Specialists announces the launch of the Prostate Vanguard, an awareness campaign to educate men about new imaging technology destined to replace multiple rectal needle biopsies of the prostate. Annually, a million men undergo random needle biopsy of the prostate gland through the rectum. Multi-parametric MRI (MP-MRI) of ...

Findings in Urology Reported from Veterans Affairs Medical Center (Multiple Repeat Prostate Biopsies and the Detection of Clinically Insignificant...
Findings in Urology Reported from Veterans Affairs Medical Center (Multiple Repeat Prostate Biopsies and the Detection of Clinically Insignificant Cancer in Men With Large Prostates) By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Health and Medicine are discussed in a new report. According to news reporting originating in Nashville, Tennessee, by NewsRx ...

Investigators at Harvard School of Public Health Report New Data on Cancer Research (Gleason grade progression is uncommon)
By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology have been published. According to news originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "Gleason grade is universally used for pathologic scoring of the differentiation of prostate cancer. However, it is unknown whether prostate tumors arise well differentiated and then ...

NCI -MD Anderson researchers discover gene that might predict aggressive prostate cancer at diagnosis
ENP Newswire - 06 October 2014 Release date- 03102014 - Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer. The results reported in the journal of Clinical Cancer Research, a publication of the American Association of Cancer ...

Studies from Ohio State University Yield New Information about Clinical Trials and Studies [The Individualized Diet and Exercise Adherence Pilot...
Studies from Ohio State University Yield New Information about Clinical Trials and Studies [The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol ...] By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Clinical Research have been presented. According to news ...

Metamark Announces Portfolio Expansion To Include PROGENSA® PCA3 And ERG Tests For Assessing Prostate Cancer
By a News Reporter-Staff News Editor at Cancer Weekly -- Metamark announced the expansion of its prostate cancer test services to now include the PROGENSA(®) PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. These tests join Metamark's current portfolio, including ProMark™, the only protein-based ...

Patent Issued for Male Urethral Prosthesis with Tensioning Member
By a News Reporter-Staff News Editor at Biotech Week -- A patent by the inventors Siegel, Steven W. (North Oaks, MN); Arnal, Kevin R. (Chanhassen, MN); Lund, Robert E. (St. Michael, MN); Anderson, Kimberly A. (Eagan, MN); Watschke, Brian P. (Eden Prairie, MN), filed on June 29, 2011, was published online on September 30, 2014, according to news reporting originating from Alexandria, Virginia, ...

ASTELLAS -U.S. FDA Approves New Indication for the Use of XTANDI (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
ENP Newswire - 11 September 2014 Release date- 11092014 - SAN FRANCISCO, CA and TOKYO, JAPAN - Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new ...

Presidential Proclamation -- National Prostate Cancer Awareness Month, 2014
NATIONAL PROSTATE CANCER AWARENESS MONTH, 2014 - - - - - - - BY THE PRESIDENT OF THE UNITED STATES OF AMERICA A PROCLAMATION Prostate cancer is one of the most common cancers among American men. They are fathers, brothers, and sons -- and this year, more than 230,000 of them are expected to be diagnosed with this disease. During National Prostate Cancer Awareness Month, we honor all those ...

RNA sequence could help doctors to tailor unique prostate cancer treatment programs
By a News Reporter-Staff News Editor at Cancer Weekly -- Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open access journal Genome Biology. Because a tumor's RNA shows the real time changes a treatment is causing, the authors think this could be a useful tool to aid diagnosis and predict ...

New recommendations for post-treatment care of prostate cancer survivors
By a News Reporter-Staff News Editor at Cancer Weekly -- Many of the more than 2.5 million men in the U.S. who have received treatment for prostate cancer deal with the often disabling side effects of surgery and radiation and hormonal therapies. To aid in the transition of these patients from specialty to primary care for long-term management of problems such as urinary incontinence and ...

Prostate cancer drug candidate shows great promise
Sept. 06--A white powdered chemical compound emerged from two University of Maryland School of Medicine laboratories more than 10 years ago with a name destined for oblivion, but a future that now looks promising as a treatment for the most challenging cases of prostate cancer. Today VN/124-1 is a drug candidate with a name, galeterone, a pharmaceutical company founded on its potential, and a ...

New Prostate Cancer Study Findings Reported from University of Kentucky (Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate...
New Prostate Cancer Study Findings Reported from University of Kentucky (Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer) By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Oncology have been presented. According to news reporting out of Lexington, Kentucky, by NewsRx editors, research stated, "The role of the androgen receptor (AR) ...

Version 2.0 of Prostate Cancer Risk Calculator now online, complete with emojis
By a News Reporter-Staff News Editor at Cancer Weekly -- A calculator to help men and their doctors assess their risk of prostate cancer, developed at the UT Health Science Center, has had a major upgrade to enhance how men and their physicians better understand a man's risk of prostate cancer (see also Prostate Cancer). A description of the update's needs and benefits is described by the ...

Tests could help men with prostate cancer
TESTING for an abnormal protein in the blood could identify men with prostate cancer who cannot be helped by two new drugs. Patients whose tumours contain a shortened protein called AR-V7 do not respond to enzalutamide and abiraterone, research has shown. The protein is detectable in the blood, raising the possibility of a test that could help doctors plan the best form of treatment for men ...

Blood test for 'nicked' protein predicts prostate cancer treatment response
By a News Reporter-Staff News Editor at Cancer Weekly -- Prostate cancer patients whose tumors contain a shortened protein called AR-V7, which can be detected in the blood, are less likely to respond to two widely used drugs for metastatic prostate cancer, according to results of a study led by researchers at the Johns Hopkins Kimmel Cancer Center. If large-scale studies validate the findings, ...

ASCO and Cancer Care Ontario Issue New Guideline on Treating Metastatic Castration-Resistant Prostate Cancer
ALEXANDRIA, Va., Sept. 8 -- The American Society of Clinical Oncology issued the following news release: The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) today issued a joint clinical practice guideline on treating men with metastatic castration-resistant prostate cancer (CRPC). The guideline includes recommendations on systemic therapies that are indicated for ...

New Prostate Cancer Study Results Reported from Johns Hopkins University School of Medicine (The role of inflammation in prostate cancer)
By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology have been published. According to news reporting originating in Baltimore, Maryland, by NewsRx journalists, research stated, "In the United States and in 'Westernized' countries, the prevalence of both prostate cancer and prostate inflammation is very high, indicating that the two pathologies could be ...

Men who are uneducated about their prostate cancer have difficulty making good treatment choices
By a News Reporter-Staff News Editor at Cancer Weekly -- They say knowledge is power, and a new UCLA study has shown this is definitely the case when it comes to men making the best decisions about how to treat their prostate cancer (see also Prostate Cancer). UCLA researchers found that men who aren't well educated about their disease have a much more difficult time making treatment ...

Age and Genetics Play a Key Role in Prostate Cancer Occurrence
By a News Reporter-Staff News Editor at Cancer Weekly -- For most men, prostate cancer is a concern after the age of 55. While the majority of prostate cancer diagnoses occur among that age group, prostate cancer does get diagnosed in men before then, and we are starting to determine reasons why. In a recent study of early onset prostate cancer out of the University of Michigan, it was found ...

Fighting prostate cancer with a tomato-rich diet
By a News Reporter-Staff News Editor at Cancer Weekly -- Men who eat over 10 portions a week of tomatoes have an 18 per cent lower risk of developing prostate cancer, new research suggests (see also Prostate Cancer). With 35,000 new cases every year in the UK, and around 10,000 deaths, prostate cancer is the second most common cancer in men worldwide. Rates are higher in developed countries, ...

Screening for prostate cancer reduces deaths by 20pc
Washington, August 7 (ANI): A new study has shown that screening for prostate cancer could reduce deaths from the disease by about a fifth. According to the long-term results of a major European study, screening appeared to reduce prostate cancer deaths by 15 percent at 9 years, and this improved to 22 percent at 11 years, and the risk of advanced prostate cancer was also smaller in the ...

Feeling Down May Up Prostate Cancer Risks
NEW YORK, NY -- (Marketwired) -- 07/31/14 -- A prostate cancer diagnosis requires immediate care and consultation with a prostate cancer expert to determine the adequate care needed for the condition. Sadly, of the number of individuals diagnosed with prostate cancer in the U.S., many die from the disease. While it is very common to correlate the numbers that have fallen to prostate cancer ...

U-M research: Late-stage prostate cancer increasing among younger men
July 17--Diagnoses of late-stage prostate cancer among younger men are on a surprising increase, with a nearly sixfold rise in diagnoses over two decades -- too much of an increase to link solely to better screening, according to a team of researchers at the University of Michigan Comprehensive Cancer Center . That, has the U-M researchers calling for a closer look at the DNA of prostate ...

Age and Genetics Play a Key Role in Prostate Cancer Occurrence
NEW YORK, NY -- (Marketwired) -- 08/05/14 -- For most men, prostate cancer is a concern after the age of 55. While the majority of prostate cancer diagnoses occur among that age group, prostate cancer does get diagnosed in men before then, and we are starting to determine reasons why. In a recent study of early onset prostate cancer out of the University of Michigan, it was found that genetics ...

Research questions prostate cancer care
July 15--Two new prostate cancer studies have found that many low-risk patients have been receiving more treatment than is needed or helpful -- racking up millions of dollars in excess health-care costs and, potentially, causing more physical harm than good. One of the studies, both of which were published Monday in JAMA Internal Medicine, showed that among patients whose cancer was not ...

Genomic analysis of prostate cancer indicates best course of action after surgery
By a News Reporter-Staff News Editor at Biotech Week -- (PHILADELPHIA) - There is controversy over how best to treat patients after they've undergone surgery for prostate cancer. Does one wait until the cancer comes back or provide men with additional radiation therapy to prevent cancer recurrence? Now, a new study from Thomas Jefferson University shows that a genomic tool can help doctors and ...

Study finds diagnosing physicians influence therapy decisions for prostate cancer patients
By a News Reporter-Staff News Editor at Biotech Week -- New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in whether older men with low-risk prostate cancer receive treatment for their disease, and if so, the type of treatment they receive as a result (see also Prostate Cancer). The findings, published in ...

New Findings on Prostate Cancer Described by Investigators at Johns Hopkins University (Enhancement of the T-cell Armamentarium as a Cell-Based...
New Findings on Prostate Cancer Described by Investigators at Johns Hopkins University (Enhancement of the T-cell Armamentarium as a Cell-Based Therapy for Prostate Cancer) By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology are discussed in a new report. According to news reporting originating from Baltimore, Maryland, by NewsRx correspondents, research ...

Reports from University of Colorado Advance Knowledge in Health Insurance [Ethnic minorities (African American and Hispanic) males prefer prostate...
Reports from University of Colorado Advance Knowledge in Health Insurance [Ethnic minorities (African American and Hispanic) males prefer prostate cryoablation as.aggressive treatment of localized prostate cancer] By a News Reporter-Staff News Editor at Insurance Weekly News -- Data detailed on Health Insurance have been presented. According to news reporting from Aurora, Colorado, by ...

Does cycling increase risk for erectile dysfunction, infertility, or prostate cancer?
By a News Reporter-Staff News Editor at Clinical Trials Week -- Cycling is a popular activity that offers clear health benefits, but there is an ongoing controversy about whether men who ride have a higher risk of urogenital disorders such as erectile dysfunction, infertility, or prostate cancer. The results of a study of nearly 5,300 male cyclists who participated in the Cycling for Health UK ...

Vasectomy may increase risk of aggressive prostate cancer
By a News Reporter-Staff News Editor at Cancer Weekly -- Boston, MA - Vasectomy was associated with a small increased risk of prostate cancer, and a stronger risk for advanced or lethal prostate cancer according to a new study from Harvard School of Public Health (HSPH). The researchers found that the association remained even among men who received regular PSA screening, suggesting the ...

Astellas and Medivation Receive Priority Review from FDA for XTANDI® (Enzalutamide) Capsules In Chemotherapy-Naive Advanced Prostate Cancer
TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) to extend the indication for XTANDI® (enzalutamide) capsules for the treatment of men with metastatic castration-resistant prostate cancer ...

Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer
JERUSALEM & VANCOUVER, British Columbia & BOTHELL, Wash.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in ...

Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX® in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place in Chicago. New data, including two oral presentations, ...

Nymox Announces Positive New Prostate Cancer Clinical Trial Results
HASBROUCK HEIGHTS, N.J., May 6, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results for this trial. A controlled comparison was conducted of patients who ...

IsoRay's Cancer Fighting Cesium-131 Isotope in Published Report Shows Significant Results in Early Clinical Interstitial Implants for Gynecologic...
IsoRay's Cancer Fighting Cesium-131 Isotope in Published Report Shows Significant Results in Early Clinical Interstitial Implants for Gynecologic Malignancies IsoRay CEO Dwight Babcock commented, "We are very excited to have our Cesium-131 isotope seeds chosen for use in the treatment of gynecologic cancers. We believe our marketing is most successful by teaming up with medical industry ...

Prostate Cancer: Watch and Wait or Ignore and Wait?
NEW YORK, NY -- (Marketwired) -- 04/25/14 -- A long-term European study highlighted key patient compliance issues in the prostate cancer active surveillance strategy. In lieu of proactive prostate cancer treatments such as robotic prostate surgery, hormone therapy, or radiation, some men choose to postpone treatment and monitor the progression of their disease. Researchers found that one ...

BPH Patients Are Not Safe Taking Testosterone, While Dr. Allen's Device Terminates Prostate Enlargement and Increases Energy Naturally, States Fine Treatment
London, GB (PRWEB) May 03, 2014 Fine Treatment recommends that a man with benign prostatic hyperplasia (BPH) should use Dr. Allen's Device in the first place, as it diminishes the enlarged prostate size naturally relieving lower urinary tract symptoms and increasing male energy. At the same time, commonly used to boost a man's energy testosterone, according to the article in the WWL-News, it ...

Vitamin D: A Sunny Outlook for Prostate Cancer
NEW YORK, NY -- (Marketwired) -- 05/08/14 -- Vitamin D deficiency could be a predictor for aggressive prostate cancer, according to a study funded by The National Institutes of Health and the U.S. Department of Defense. In examining the prostate biopsy results of men with abnormal prostate-specific antigen (PSA) levels and/or digital rectal exams (DREs), researchers discovered that men with ...

New Model Can Predict Therapy Outcomes in Prostate Cancer with Bone Metastasis
PHILADELPHIA, May 1 -- The American Association for Cancer Research issued the following news release: A new computational model that simulates bone metastasis of prostate cancer has the potential to rapidly assess experimental therapy outcomes and help develop personalized medicine for patients with this disease, according to data published in Cancer Research, a journal of the American ...

Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug
NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center, reaffirmed his commitment to lead AV Therapeutics' Phase I clinical trial ...

Prostate Cancer Foundation Receives over $8.4M Movember Donation
SANTA MONICA, Calif.--(BUSINESS WIRE)-- The Prostate Cancer Foundation (PCF) has received over $8.4 million from its partner Movember, the global men’s health charity that gets men to grow and women to support the moustache for the month of November, raising vital funds and awareness for men’s health. PCF will allocate the over $8.4 million to find better treatments and ultimately a cure, by ...

 
 

Facebook - UsToo.org  Twitter - UsToo.org  LinkedIn - UsToo.org Inspire prostate cancer discussions – UsToo.org 

Contact Us | Privacy Policy | Terms & Conditions | Disclaimer   

 
Copyright © 2005-2014 Us TOO International, Inc.
Designed and hosted by ACCESS Medical Group, Ltd.